首页> 外国专利> IDENTIFICATION OF A NEW MOLECULAR FACTOR FOR EARLY DIAGNOSIS OF UROTHELIAL CARCINOMA OF THE BLADDER

IDENTIFICATION OF A NEW MOLECULAR FACTOR FOR EARLY DIAGNOSIS OF UROTHELIAL CARCINOMA OF THE BLADDER

机译:膀胱尿路上皮癌早期诊断的新分子因子的鉴定

摘要

The present invention relates to the identification of a new molecular factor for the early diagnosis of urothelial carcinoma of the bladder. HtrA1 is a molecule that is produced mainly by the urothelium of the bladder, both in physiological and inflammatory pathologies, such as cystitis, whereas it is absent in the urothelial layer of the neoplastic bladder mucosa, regardless of cancer grade and level. By means of Western Blotting two forms of HtrA1 were identified, both in bladder tissue and urine, the native 50 kDa form and the autocatalytic 38 kDa form. The 38 kDa form of HtrA1 is significantly underexpressed in tumoral tissues compared with normal tissues and concentration of the 50 kDa form of HtrA1 in urine is significantly higher in patients affected by bladder cancer compared to healthy subjects and subjects with cystitis. Therefore, the evaluation of tissutal and urinary HtrA1 levels can be a specific marker of urothelial carcinoma of the bladder, able to early recognize its presence.
机译:本发明涉及用于早期诊断膀胱尿路上皮癌的新分子因子的鉴定。 HtrA1是一种分子,主要在生理和炎症病理(例如膀胱炎)中由膀胱尿路上皮产生,而在肿瘤膀胱粘膜的尿路上皮层中不存在,无论癌症的级别和水平如何。通过蛋白质印迹法,在膀胱组织和尿液中鉴定出两种形式的HtrA1,天然的50 kDa形式和自催化的38 kDa形式。与正常组织相比,在肿瘤组织中38 kDa形式的HtrA1明显表达不足,与健康受试者和膀胱炎受试者相比,膀胱癌患者的尿液中50 kDa形式的HtrA1浓度明显更高。因此,组织和尿液HtrA1水平的评估可以作为膀胱尿路上皮癌的特异性标志物,能够及早识别其存在。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号